Table 3 Univariate and multivariate cox proportional hazards analysis of clinicopathologic variables and 21-gene risk score for event-free survival.
From: Development and validation of a 21-gene prognostic signature in neuroblastoma
Univariate | p-value | Multivariate | p-value | ||
|---|---|---|---|---|---|
HR | HR | ||||
(95% CI) | (95% CI) | ||||
GSE85047 (N = 240, events = 94) | Age at Diagnosis | 3.786 | < 0.0001 | 1.769 | 0.03810 |
(> 18 Months vs. < 18 Months) | (2.355–6.087) | (1.032–3.033) | |||
INSS Stage | 6.090 | < 0.0001 | 2.950 | 0.00595 | |
(III, IV vs. I, II) | (3.056–12.140) | (1.365–6.378) | |||
MYCN Status | 3.373 | < 0.0001 | 1.676 | 0.02464 | |
(Amplified vs. Unamplified) | (2.226–5.112) | (1.068–2.631) | |||
21-gene risk score | 3.736 | < 0.0001 | 1.772 | 0.03608 | |
(High vs. Low) | (2.357–5.924) | (1.038–3.026) | |||
E-MTAB-179 (N = 416, events = 140) | Age at Diagnosis | 3.565 | < 0.0001 | 1.272 | 0.25546 |
(> 18 Months vs. < 18 Months) | (2.501–5.083) | (0.8402–1.926) | |||
INSS Stage | 5.172 | < 0.0001 | 2.782 | < 0.0001 | |
(III, IV vs. I, II) | (3.354–7.976) | (1.7385–4.451) | |||
MYCN Status | 4.025 | < 0.0001 | 1.685 | 0.00766 | |
(Amplified vs. Unamplified) | (2.807–5.771) | (1.1482–2.472) | |||
21-gene risk score | 5.869 | < 0.0001 | 3.024 | < 0.0001 | |
(High vs. Low) | (3.825–9.006) | (1.8148–5.040) |
